Changes of CD4＋ CD25＋ Regulatory T Cells in Peripheral Blood in Patients with Hepatocellular Carcinoma Before and after TACE

This study investigated the changes of CD4＋ CD25＋ regulatory T cells （Tregs） in periph-eral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoem-bolization （TACE）. The proportion of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups： 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4＋CD25＋ Tregs among CD4＋ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant （P〈0.01） between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE （P〈0.01）, whereas, that in group B was increased significantly 1 month after TACE （P〈0.01）. It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4＋CD25＋ Tregs in peripheral blood. TACE did not significantly affect the level of CD4＋ CD25＋ Tregs within short time （such as 1 week）. The proportion of CD4＋CD25＋ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.     

CD4^＋CD25^high Regulatory Cells in Peripheral Blood of NSCLC Patients

The proportion and changes of CD4 CD25high regulatory T cells (Trs) in peripheral blood of non-small cell lung cancer (NSCLC) patients were analyzed and their clinical significance explored. The peripheral blood was collected from 61 patients with NSCLC and 15 healthy controls. By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for lymphocyte subsets (CD3 , CD4 and CD8 ) and CD4 CD25high Tr cells. The results showed that the proportion of CD4 CD25high Tr cells in NSCLC group was significantly higher than in control group [(4.36±2.07) % vs (2.04±1.03) %, P<0.01]. The proportion of CD4 CD25 high Tr cells in late stage was higher than that in early stage [stages I II (2.26 0.6) %; stage III (3.28 1.38) %; stage IV (6.06±4.08) %] (P<0.05). Kaplan-Meier survival analysis revealed that the prognosis of the patients who had higher proportion of CD4 CD25high Tr cells in peripheral blood was worse (P=0.0026). In conclusion, the relative increase in CD4 CD25high Tr cells in peripheral blood may be related to im-munosuppression and tumor progression in patients with NSCLC. This finding suggests that CD4 CD25 high Tr cells in peripheral blood of NSCLC may be positive for prognosis analysis. The use of depletion of the CD4 CD25high Tr cell therapy to treat NSCLC patients may be an effective strategy.     

Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients

Background Different strategies for hepatocellular carcinoma （HCC） may have distinct effects on the immune system.The aim of this research was to investigate changes in the immunological function after transcatheter arterial chemoembolization （TACE） plus radiofrequency ablation （RFA） in HCC patients.Methods A total of 51 consecutive HCC treatment-naive patients was enrolled in this study and 20 healthy subjects served as controls.The therapeutic strategy was selected according to the tumor stage and general conditions.TACE was performed in 25 cases,TACE plus RFA in 17 and RFA in nine.All the patients underwent routine examinations and peripheral blood was harvested for the detection of lymphocyte subset by flow cytometry 1 day before,and 2 and 4 weeks after the treatment.The serum levels of alpha-fetoprotein （AFP）,ALT and AST were also measured before and 4 weeks after treatment for the evaluation of therapeutic efficacy and liver function impairment.Results When compared with healthy controls,the CD4/CD8 ratio and the number of B cells and natural killer （NK） cells were significantly decreased in HCC patients before treatment （P 〈0.05）.When compared with before treatment,the CD4＋ cells and CD4/CD8 ratio decreased but CD8＋ cells increased in the TACE group （P 〈0.05）; the CD4/CD8 ratio and NK cells decreased but CD8＋ cells increased in the TACE-RFA group （P 〈0.05）; the CD3＋ cells,CD4＋ cells,CD4/CD8 ratio and NK cells increased in the RFA group （P 〈0.05）.Significant differences in the CD3＋ cells,CD8＋ cells,CD4/CD8 ratio and NK cells were observed among groups （P 〈0.05）.Moreover,the AFP level decreased and transaminase level increased in all groups （P 〈0.05）.Differences of pre and post treatment between groups were statistically significant （P =0.016,0.025,0.018 respectively）.Conclusions Immunity was compromised in HCC patients; TACE and TACE plus RFA lowered immunologic function to a certain extent.RFA improved it accompanied by a protective effect on liver function.     

Effect of Tiotropium Bromide on Expression of CD_8~＋CD_（25）~＋FoxP_3~＋ Regulatory T Cells in Patients with Stable Chronic Obstructive Pulmonary Disease

The expression of CD8+CD25+FoxP3+ regulatory T cells(CD8+Tregs) in the peripheral blood of patients with stable chronic obstructive pulmonary disease(COPD),and the effect of muscarinic cholinergic receptor antagonist tiotropium bromide on the expression of CD8+Tregs were investigated.Twenty-three patients with moderate to severe stable COPD were enrolled in this study.All patients inhaled tiotropium bromide(18 μg daily) for 3 months.Before and after inhalation of tiotropium bromide,peripheral blood samples were collected from the patients,and T cells were labeled by three-color labeled monoclonal antibodies.Flow cytometry was used to detect the quantity and percentage of CD8+T cells,CD8+CD25+T cells,CD8+Tregs,CD4+T cells,CD4+CD25+T cells and CD4+CD25+FoxP3+ regulatory T cells(CD4+Tregs) respectively.The percentage of CD4+T cells was increased from(27.82±2.18)% to(35.53±1.3)%(t=3.20,P=0.004) in the peripheral blood of patients with stable COPD after inhalation of tiotropium bromide for 3 months,that of CD4+CD25+T cells was decreased from(10.03 ±1.42)% to(4.21 ±0.65)%(t=3.78,P=0.001),and that of CD8+Tregs was increased from(8.41 ±1.68)% to(21.34 ±4.20)%(t=2.72,P=0.013).At baseline,CD8+T cells,CD8+CD25+T cells and CD4+Tregs were detectable in the peripheral blood,but no significant changes were observed after treatment.Linear correlation analysis revealed that the difference before and after treatment in CD4+T cells and CD4+CD25+T cells was negatively correlated with the ratio of change in CD8+Tregs before and after treatment(r=-0.61,P=0.013;r=-0.72,P=0.001 respectively).In the peripheral blood of patients with stable COPD,there was the expression of CD8+Tregs and CD4+Tregs.Muscarinic receptor antagonist,tiotropium bromide,can promote the amplification of CD4+T cells,inhibit the expression of CD25+T cells,and enhance the expression of CD8+Tregs.CD8+Tregs and CD4+Tregs can be used as new indicators to understand the immune status of patients.They are helpful in judging the treatment efficacy and disease immunophenotype.     

Relationship between the Changes of VEGF Level and Dendritic Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

In order to investigate the relationship between the VEGF level and the counts of den-dritic cells (DCs) in peripheral blood of patients with hepatocellular carcinoma (HCC) before and af-ter transcatheter arterial chemoembolization (TACE), the peripheral blood was obtained from 37 pa-tients with HCC who treated by TACE. The blood was obtained on the day before TACE, the first day, the 7th day and the 15th day after TACE respectively. The counts of DCs were quantified by flow cytometry. The plasma VEGF level was measured by ELESA kit. It was shown after TACE, the counts of DCs in peripheral blood were decreased significantly (P<0.05), and the VEGF level in pe-ripheral blood was increased significantly (P<0.05). The counts of DCs in peripheral blood had an inverse correlation with the plasma VEGF level (r=-0.57, P<0.05) after TACE. It was concluded that in patients with HCC after TACE, the increased plasma VEGF level appeared to have the effect to suppress the maturation of DCs, which may contribute to reduction of the body's anti-tumor im-munity effect, with a consequence of recur and metastasis of tumor.     

Analysis of CD4^＋CD25^＋ Regulatory T Cells and Foxp3 mRNA in the Peripheral Blood of Patients with Asthma

The changes of CD4 CD25 regulatory T cells (CD4 CD25 Treg) and Foxp3 mRNA in peripheral blood mononuclear cells (PBMCs) from patients with asthma were investigated in order to elucidate the possible roles of CD4 CD25 Treg in the development of asthma. The peripheral blood samples were collected from 29 healthy controls (normal control group) and 78 patients with asthma which included 30 patients in exacerbation group, 25 patients in persistent group, and 23 patients in remission group. By using flow cytometry and RT-PCR, the CD4 CD25 Treg ratio and Foxp3 mRNA in PBMCs were detected. The CD4 CD25 Treg ratio and Foxp3 mRNA in PBMCs of exac-erbation and persistent groups were lower than that of remission and normal control groups (P<0.05). Although the CD4 CD25 Treg ratio and Foxp3 mRNA of remission group were also lower than that of normal control group, there was no significant difference between them (P>0.05). As compared with persistent group, exacerbation group had lower CD4 CD25 Treg ratio and Foxp3 mRNA (P<0.05). It was indicated that the decrease of CD4 CD25 Treg ratio and its function in PBMCs may be responsible for pathogenesis of asthma.     

Changes of Regulatory T Cells in Graves' Disease

The immune mechanism of Graves' diseases (GD) and the roles of regulator T cells were investigated. In 32 patients with GD (GD group) and 20 healthy volunteers (control group), flow cy-tometry was used to detect the proportion of CD4 CD25 cells, MACS to isolate CD4 CD25 cells, RT-PCR to assay the expression of FOXP3, and ELISA to test the level of IL-10, respectively. It was found that there was no significant change in the proportion of CD4 CD25 T cells between GD group and control group (P>0.05), while secretion of IL-10 and expression of FOXP3 in GD group were lower than control group (P<0.01 and P<0.05, respectively). In conclusion, though the proportion of regulatory T cells of peripheral blood lymphocytes in the patients with GD, the functions of them were significantly weakened, which might be a pathogenic factor in GD.     

Changes of CD4^＋CD25^＋ Regulatory T Cells in Patients with Acute Coronary Syndrome and the Effects of Atorvastatin

The function of CD4＋CD25＋ regulatory T lymphocytes （Treg） in patients with acute coronary syndrome （ACS） and the effects of atorvastatin were investigated. Forty-eight patients with ACS were randomly divided into two groups： group C receiving conventional therapy （n=24）, and group C＋A receiving conventional therapy＋atorvastatin （10 mg/day, n=24）. T lymphocytes from ACS patients （before and 2 weeks after the treatment） or 18 healthy subjects were separated and the flow cytometry was used to measure the percentage of Treg. The inhibitory ability of Treg on effector T cells was determined by mixed lymphocyte reaction （MLR）. ELISA was used to measure the serum levels of cytokines （IL-10, TGF-β1 and IFN-γ） before and after treatment. The results showed that as compared with normal control group, Treg percentage was decreased significantly （P〈0.01）, the inhibitory ability of Treg on the T lymphocytes proliferation was reduced （P〈0.01）, IFN-γ levels were increased and IL-10 and TGF-β1 levels were lowered in ACS patients. After treatment with atorvastatin, Treg percentage and the inhibitory ability of Treg on T lymphocytes proliferation were significantly increased in ACS patients. Serum IFN-γ was decreased significantly, while IL-10 and TGF-β1 were elevated significantly as compared with the non-atorvastatin group. The number of Treg was positively correlated with serum TGF-β1, but negatively with serum IFN-γ and CRP. It was concluded that ACS was associated with decreased number and defected function of Treg, which may play an important role in initiating immune-inflammatory response in ACS. The inhibitory effects of atorvastatin on inflammation in ACS may be due to its beneficial effects on Treg and restoration of immune homeostasis.     

Correlation of Thl7 cells and CD4＋CD25＋ regulatory T cells with clinical parameters in patients with systemic sclerosis

Background Systemic sclerosis （SSc） is an autoimmune disease that has three major components： inflammation, fibrosis, and vasculopathy. T-helper 17 cell （Th17） and regulatory T cell （Treg） are considered to be critical for autoimmune disease pathogenesis. The role of Th17 and Treg in SSc is still unclear. The aim of this study was to detect the presence of Th17s and CD4＊CD25~ Tregs in peripheral blood samples from SSc patients and to investigate the possible roles of these two T cell subsets in SSc pathogenesis. Methods Th17s （CD4 and IL-17 positive） and CD4＊CD25~ Tregs （CD4, CD25 and Foxp3 positive） in the peripheral blood mononuclear cells of 53 SSc patients and 27 healthy controls were counted by flow cytometry. The differences between SSc and control patients were analyzed. Clinical parameters, including disease duration, duration of the second symptoms, Modified Rodnan Skin Score （MRSS）, anti-topoisomerase I antibody, anti-U1 ribonucleoprotein （RNP） antibody, systemic involvements, pulmonary function test （PFT） and high resolution computed tomography （HRCT） score were prospectively collected following EUSTAR （EULAR scleroderma trial and research group） protocols. The correlations between the experimental and clinical data were investigated. Results The ratio of Th17 in SSc patients was significantly elevated compared to healthy controls （8.74% vs. 4.41%, P 〈0.001）. The amount of Th17 was positively correlated with disease duration （R=-0.531, P=-0.013） and duration of the second symptoms （R=-0.505, P=0.023）. The ratio of CD4＊CD25＊ Treg in SSc patients also significantly differed from the healthy controls （3.04% vs. 2.24%, P=0.018）. Elevated Tregs were more frequently observed in patients with a high interstitial lung disease （ILD） score on computed tomography （24/36） compared with patients with normal ILD scores （4/12, ,P=-0.043）. Elevated Tregs were also more often observed in patients with low carbon monoxide diffusing capacity     

Changes of Regulatory T Cells in Graves＇ Disease

The immune mechanism of Graves＇ diseases （GD） and the roles of regulator T cells were investigated. In 32 patients with GD （GD group） and 20 healthy volunteers （control group）, flow cytometry was used to detect the proportion of CD4^＋CD25^＋ cells, MACS to isolate CD4^＋ CD25^＋ cells, RT-PCR to assay the expression of FOXP3, and ELISA to test the leyel of IL-10, respectively. It was found that there was no significant change in the proportion of CD4^＋CD25^＋ T cells between GD group and control group （P〉0.05）, while secretion of IL-10 and expression of FOXP3 in GD group were lower than control group （P〈0.01 and P〈0.05, respectively）. In conclusion, though the proportion of regulatory T cells of peripheral blood lymphocytes in the patients with GD, the functions of them were significantly weakened, which might be a pathogenic factor in GD.     

肝动脉化疗栓塞术对原发性肝癌合并HIV/AIDS患者T淋巴细胞亚群的影响

目的 探讨原发性肝癌(primary hepatic carcinoma,PHC)合并人类免疫缺陷病毒(human immunodeficiency virus,HIV)/获得性免疫缺陷综合征(acquired immune deficiency syndrome,AIDS)患者肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)前后T细胞亚群的变化.方法 采用回顾性病例对照研究,选取2014年7月至2016年6月在成都市公共卫生临床医疗中心就诊的17例PHC合并HIV/AIDS患者为试验组,同期HIV阴性的PHC患者32例为对照组.采用流式细胞术(FCM)检测两组患者术前1 d及试验组患者术后1、4周外周血CD3、CD4、CD8 T细胞及CD4/CD8的比值,比较两组患者术前1 d及试验组术后1、4周外周血T细胞亚群各指标的动态变化.结果 试验组术前外周血T细胞亚群CD3、CD4、CD4/CD8比值明显低于对照组,而CD8明显高于对照组(P<0.05);试验组治疗1周后,外周血T细胞亚群CD3、CD4、CD4/CD8比值明显较治疗前下降,CD8明显增高(P<0.05),而4周后外周血T细胞亚群CD3、CD4及CD4/CD8比值较治疗1周后明显增高,CD8明显下降(P<0.05).结论 TACE对PHC合并HIV/AIDS患者是安全、有效的治疗方法.PHC合并HIV/AIDS患者细胞免疫较HIV阴性的PHC患者明显低下,TACE治疗PHC合并HIV/AIDS患者,细胞免疫状态呈现先抑制后恢复的趋势.     

胃肠道恶性肿瘤患者CD4+CD25+调节性T细胞的检测及意义

目的探讨胃肠道恶性肿瘤患者外周血及病理组织调节性T细胞(Tregs)的表达及临床意义。方法采用流式细胞仪对60例胃肠道恶性肿瘤患者及20例健康对照者外周血CD4+CD25+Foxp3+T细胞占CD4+T细胞(CD4+CD25+Foxp3+Tregs/CD4+T)的比率进行检测,采用免疫组化法检测相应患者病理组织中CD4+CD25+Foxp3+Tregs的表达水平。结果胃癌、结直肠癌患者外周血CD4+CD25+Foxp3+Tregs/CD4+T细胞的比率分别为(7.46±0.85)%和(7.79±1.19)%,与对照组(6.65±0.79)%比较,差异有统计学意义(P<0.01)。胃癌、结直肠癌病理组织中CD4+CD25+Foxp3+Tregs的表达平均阳性细胞绝对数为(53.52±16.31)和(58.15±14.86),与癌旁组织(6.53±2.68)比较,差异有统计学意义(P<0.01)。结论胃癌、结直肠癌患者外周血及病理组织中Tregs的高表达可能具有肿瘤免疫的抑制作用,并与肿瘤的发生、发展密切相关。     

类风湿关节炎患者外周血CD4+T细胞CD25及CD127的表达

目的 探讨类风湿关节炎(RA)患者外周血调节性T细胞(Tregs)比例的变化情况,了解Tregs变化在RA发病及炎症活动中的意义.方法 采用流式细胞仪三色荧光抗体标记法分别对25例RA患者和31名健康志愿者(HV)的外周血淋巴细胞进行CD4、CD25及CD127标记,分析比较RA患者组与HV组间淋巴细胞中CD4+CD25+、CD4+CD25high、CD4+CD25+CD127-及CD4+CD25highCD127-细胞比例的差异情况,并将RA组相应细胞比例与RA疾病活动性评分(DAS28-4)、压痛关节数、肿胀关节数、晨僵时间、医生和患者对疾病活动性的整体评价(VAS)、血红细胞沉降率、C-反应蛋白行相关分析.结果 RA组外周血淋巴细胞中,CD4+CD25+CD127-和CD4+CD25highCD127-细胞占CD4+T淋巴细胞的百分率分别为(2.53±0.85)%和(0.91±0.32)%,而HV组则分别为(3.22±0.97)%和(1.25±0.41)%.CD4+CD25+CD127+和CD4+CD25highCD127-细胞比例在RA组均明显低于HV组,其组间差异均有统计学意义(均P<0.05);另外,RA患者CD4+CD25+CD127-和CD4+CD25highCD127-T细胞比例均与DAS28-4及压痛关节数存在负相关(P<0.05),CD4+CD25highCD127-T细胞还与肿胀关节数及患者VAS存在负相关(P<0.05).结论 RA患者外周血淋巴细胞存在Tregs比例的降低,Tregs数量的异常可能是RA发病及炎症活动的重要影响因素.     

慢性乙型肝炎患者CD4+ CD25+调节性T细胞免疫抑制功能的研究

目的 探讨慢性乙型肝炎患者CD4+ CD25+调节性T细胞(Treg)免疫抑制功能.方法 收集北京大学人民医院22例慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMC)以及18名健康对照的PBMC标本,以流式分析对PBMC中CD4+ CD25+ Treg的频率进行分析;5-溴脱氧尿嘧啶核苷(BrdU)掺入法评价CD4+ CD25+ Treg的免疫抑制功能;并同时通过磁珠分选去除CHB患者PBMC中的CD4+ CD25+ Treg,分别以MHC-肽-五聚体法和酶联斑点免疫法(Elispot)检测HBVcore18-27抗原肽刺激对HBV特异性的细胞毒性T淋巴细胞(CTLs)的频率以及IFN-γ的分泌.结果 CHB患者外周血中CD4+ CD25+ Treg细胞群所占CD4+T细胞群的比例明显高于健康对照(t=3.74,P＜0.01);CHB患者CD4+ CD25+ Treg细胞可非特异抑制自身活化的CD4+ CD25- T细胞,并呈剂量依赖的特点,且抑制能力与健康对照相比无明显差异;在经HBVcore18-27抗原肽诱导条件下,去除CD4+ CD25+ Treg CHB患者,HBVcore18-27特异性CTLs的频率以及CTLs分泌IFN-γ的频数与未去除CD4+ CD25+ Treg组比出现显著上调(t=4.75,t=7.828,P＜0.01).结论 CHB患者循环中CD4+ CD25+ Treg细胞频率升高.在体外去除CHB患者PBMC的CD4+ CD25+ Treg后可显著地增强HBV抗原诱导的抗HBV细胞免疫应答.     

化疗对食管癌患者外周血CD4+CD25+调节性T细胞的影响

目的  探讨化疗对食管癌术后患者外周血CD4+CD25+调节性T细胞的影响。方法  随机选择35例食管癌术后化疗患者,应用流式细胞仪检测其化疗前、化疗1周后外周血CD4+CD25+调节性T细胞的比例,并进行比较,选择30例健康志愿者作为对照。结果  食管癌患者术后化疗前外周血中CD4+CD25+调节性T细胞的比例(10.44±1.45)%高于同期健康对照组（9.35±1.41）%,差异有统计学意义（t=3.059,P＜0.05）。35例患者其化疗前及化疗1周后外周血CD4+CD25+调节性T细胞比例分别为：(10.44±1.45)%、(11.67±1.56)%,两者比较差异具有统计学意义（t=6.342,P＜0.01）。结论  化疗可增高食管癌术后患者外周血CD4+CD25+调节性T细胞的比例。     

原发性胰腺癌患者高强度聚焦超声治疗前后外周血CD4+CD25+调节性T细胞的变化及其意义

目的：探讨原发性胰腺癌患者接受高强度聚焦超声(HIFU)治疗前后外周血CD4+
CD25+调节性T细胞的变化,阐明HIFU治疗对原发性胰腺癌患者免疫功能的影响。方
法：原发性胰腺癌组患者36例,对照组体检健康者28例,于HIFU治疗前、治疗4周后分别抽取外周静脉血,采
用流式细胞术检测外周血中CD4+CD25+调节性T细胞的百分比,并比较治疗前后原发性胰
腺癌患者KPS评分和癌胚抗原（CEA）、糖类抗原199（CA-199）水平的变化。结果： HIFU治疗前原发性胰腺癌组患者
外周血CD4+ CD25+ 调节性T细胞百分比高于对照组,差异有统计学意义（P<0.01）;原发性胰腺癌组患者经HIFU治疗4周后外周血CD4+CD25+调节性T细胞百分比较治疗前明显下降,差异有统计学意义（P<0.01）。原发性胰腺癌组患者治疗后KPS评分与治疗前比较明显上升,差异有统计学意义（P<0.05）;CEA和CA-199水平与治疗前比较均明显下降,差异有统计学意义（P<0.05）。结论：HIFU治疗可以改善原发性胰腺癌患者的细胞免疫功能。     

食道癌患者CD4^＋、CD25^＋、Foxp3^＋调节性T细胞的变化及意义

[目的]初步探讨CD4^＋CD25^＋Foxp3^＋调节性T细胞在食道癌患者外周血中的变化及临床意义。[方法]59例食道癌患者,分为鳞癌组47例,腺癌组12例,另外30例健康志愿者为对照组,用流式细胞术分别检测外周血中CD4^＋、CD25^＋、Foxp3^＋T细胞占CD4^＋T细胞的比例。[结果]食道癌初诊患者组CD4^＋、CD25^＋、Foxp3^＋T细胞比例为（10．33±5．72）％,明显高于健康志愿者组（4．56±1．06）％（P〈0．01）,而食道鳞癌组和食道腺癌组CD4^＋、CD25^＋、Foxp3^＋T细胞比例没有明显差异。[结论]CD4^＋、CD25^＋、Foxp3^＋调节性T细胞在食道癌初诊患者外周血中比例增加,可能是食道癌免疫抑制的一个重要原因。     

胃癌手术前后外周血CD4^＋CD25^＋调节性T细胞的变化及临床意义

目的：检测CD4^＋CD25^＋调节性T细胞（Treg）在胃癌手术前后外周血中的变化,探讨Treg在肿瘤免疫中的作用。方法：收集初治胃癌患者38例作为研究对象,同时收集20例健康人外周血作为正常对照组。检测手术前3d和手术后14d外周血中CD4^＋CD25^＋Treg比例及T细胞亚群,将各检测结果结合临床、病理指标进行统计学分析。结果：胃癌患者术前外周血中Treg比例显著高于术后比例以及对照组（P均〈0．01）。胃癌患者术前外周血CD8^＋T细胞比例明显低于术后比例以及对照组（P均〈0．01）。术前外周血CD8^＋T细胞比例与Treg比例呈负相关（P〈0．05）。胃癌患者术前外周血中Treg比例在不同淋巴结转移情况和TNM分期之间差异具有统计学意义（P〈0．05）,其与淋巴结转移和TNM分期呈正相关（P〈0．01）。胃癌患者手术后Treg比例较术前下降,且下降程度与浸润深度、淋巴结转移、远处转移、TNM分期、分化程度、病理分型以及手术方式无相关性。结论：Treg可能通过抑制CD8^＋T细胞的增殖及功能,促进肿瘤细胞的生长和发展。Treg与肿瘤的侵袭、淋巴结转移有关,提示Treg在一定程度上可作为检测疾病进展的免疫学指标。     

联合放化疗对鼻咽癌患者CD4＋/CD25＋与CD28＋/TCR＋T淋巴细胞亚群的影响

目的：研究鼻咽癌患者联合放化疗前后CD4＋/CD25＋与CD28＋/TCR＋T淋巴细胞亚群的变化。方法：招募43例接受联合放化疗的鼻咽癌患者,在联合放化疗前、联合放化疗3周及6周后分别抽取外周静脉血,运用葡聚糖-泛影葡胺密度梯度离心法分离并收集淋巴细胞,流式细胞仪检测CD4＋/CD25＋与CD28＋/TCR＋T淋巴细胞亚群的比例。结果：联合放化疗3周及6周后CD4＋/CD25＋淋巴亚群无明显变化（P〉0.05）,CD28＋/TCR＋淋巴亚群明显升高（P〈0.05）。结论：联合放化疗可部分恢复鼻咽癌患者受抑制的免疫功能。